Clinical Trial Update: Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. [Phase 3]

View source ↗

Summary

Phase 3 single-arm, open-label trial evaluating switching from anti-C5 therapy to iptacopan for 24 weeks in patients with paroxysmal nocturnal hemoglobinuria. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED | Results posted: 2025-12-15